The Daily Mail publishes coverage about a “forgotten” slimming pill, presenting it as a potential alternative to well-known weight-loss treatments such as Mounjaro (tirzepatide) and Wegovy (semaglutide). The article positions the product as potentially cheaper and as being particularly suited to people who experience binge-eating or strong food cravings.
The outlet frames the story around the broader popularity of injectable GLP-1 and related weight-loss drugs, noting that they have high-profile visibility through celebrity association. However, the coverage emphasizes consumer-facing comparisons—cost and which appetite or eating-behavior patterns the pill is said to target—rather than providing detailed, outlet-specific trial results or regulatory context in the supplied excerpts.
Across the two provided sources, the wording and emphasis are the same, with both referring to the pill being “forgotten,” “cheaper,” and potentially beneficial for binge-eaters and people with cravings, while also contrasting it with the mainstream recognition of Wegovy and Mounjaro.
